secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0001193125-23-241943
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha doses second Rett syndrome patient with TSHA-102 in REVEAL Phase 1/2 adult trial
--------------------------------------------------------------------------------

- Second adult patient dosed with TSHA-102 in REVEAL Phase 1/2 adult trial for Rett syndrome in Canada.
- Clinical data from both low-dose adult patients to be reported on mid-November earnings call after IDMC review.
- Enrollment completion in low-dose cohort (third patient) expected Q4 2023.
- First pediatric patient dosing expected Q1 2024; FDA cleared pediatric IND.
- UK MHRA CTA for pediatric patients submitted; feedback expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523241943/0001193125-23-241943-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523241943/d529272d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-241943

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer